跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
JAMP EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
JAMP EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE
Authorized
STANDARD
JAMP EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE
Jamp Pharma Corporation
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
e17d9c4a45293253
Company
Jamp Pharma Corporation
Type
Standard
Approval Details
Approval Id
e17d9c4a45293253
Drug Approval Canada Name
JAMP EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE
Product Name
JAMP EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE
Status
Marketed
Status Date
2019-07-23
Original Market Date
2019-07-23
Din
02487012
Drug Class
Human
Dosage Form
Tablet
Route Of Administration
Oral
Schedule
Prescription
Ahfs
08:18.08.20
Atc Original
J05AR03 TENOFOVIR DISOPROXIL AND EMTRICITABINE
Atc Name
j 05 ar 03
Aig Number
0251568001
Company Name
Jamp Pharma Corporation
Company Address
1310 Rue Nobel, Boucherville, Quebec, Canada, J4B 5H3
Company Detail Path
/organization/jamp-pharma-corporation
Company Information
Pharmaceutical Company Name
Jamp Pharma Corporation
Country Name
Canada
Province Name
British Columbia
City Name
chilliwack,british columbia,country_ca
Address
8065 Aitken Rd
Active Ingredients
EMTRICITABINE
200 MG
TENOFOVIR DISOPROXIL FUMARATE
300 MG
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
e17d9c4a45293253
Type
Standard
Back to Health Canada Approvals
